| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
CRISPR-Cas9 gene editing for patients with haemoglobinopathies
|
The Lancet Haematology,
|
|
2019
|
6 |
9 |
p. e438
|
article
|
| 2 |
Direct oral factor Xa inhibitors in patients with morbid obesity
|
Summers, Katherine L
|
|
2019
|
6 |
9 |
p. e446
|
article
|
| 3 |
Direct oral factor Xa inhibitors in patients with morbid obesity – Author's reply
|
Kushnir, Margarita
|
|
2019
|
6 |
9 |
p. e447
|
article
|
| 4 |
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study
|
Ravandi, Farhad
|
|
2019
|
6 |
9 |
p. e480-e488
|
article
|
| 5 |
Is chemoimmunotherapy maintenance of value in patients with chronic lymphocytic leukaemia and minimal residual disease?
|
Fink, Anna M
|
|
2019
|
6 |
9 |
p. e441-e442
|
article
|
| 6 |
Non-allogeneic immunotherapy in acute myeloid leukaemia
|
Adès, Lionel
|
|
2019
|
6 |
9 |
p. e443-e444
|
article
|
| 7 |
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial
|
Michallet, Anne-Sophie
|
|
2019
|
6 |
9 |
p. e470-e479
|
article
|
| 8 |
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
|
Usmani, Saad Zafar
|
|
2019
|
6 |
9 |
p. e448-e458
|
article
|
| 9 |
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
|
Mateos, Maria-Victoria
|
|
2019
|
6 |
9 |
p. e459-e469
|
article
|
| 10 |
The future of checkpoint inhibition in multiple myeloma?
|
Costello, Caitlin
|
|
2019
|
6 |
9 |
p. e439-e440
|
article
|
| 11 |
The Lancet Haematology 2020: call for papers
|
del Pozo Martín, Yaiza
|
|
2019
|
6 |
9 |
p. e445
|
article
|
Journal description